Results 41 to 50 of about 2,401 (204)
Volumetric absorptive microsampling for the therapeutic drug monitoring of psychiatric patients treated with cariprazine [PDF]
, 2023 Psychiatric disorders are usually treated with antipsychotic agents belonging to different pharmacological and chemical classes, the most recent ones collectively known as “third-generation antipsychotics”, such as cariprazine, approved in 2015 for the ...
Mondella, Fortunata +22 more
core +1 more source
Cariprazine on Psychosis: Beyond Schizophrenia – A Case Series
Neuropsychiatric Disease and Treatment, 2022 Miguel Bajouco,1– 3 David Mota1,2 1Department of Psychiatry, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; 2Institute of Psychological Medicine, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 3Coimbra Institute for ...
Bajouco M, Mota D
doaj
European Psychiatry, 2022 Introduction The discovery of second-generation antipsychotics represented an authentic breakthrough for the management of psychotic disorders. Nevertheless, they still don’t adequately manage some aspects of these disorders, such as negative symptoms ...
C. Llach +5 more
doaj +1 more source
Cariprazine in the treatment of psychosis with comorbid cannabis use: A case report
Psychiatry Research Communications, 2022 Past literature highlights that cannabis use increase the risk of developing psychotic disorder. In this case report, the authors describe the employment of cariprazine in the treatment of a young adult male affected by psychosis and co-morbid cannabis ...
Alessandro Gentile +4 more
doaj +1 more source
Cariprazine in Bipolar Disorder: Clinical Efficacy, Tolerability, and Place in Therapy [PDF]
, 2013 Cariprazine is a dopamine D3-preferring D3/D2 receptor partial agonist in late-stage clinical development for the treatment of bipolar disorder (manic/mixed and depressive episodes), as well as for schizophrenia, and as an adjunctive agent for the ...
Citrome, Leslie, Leslie Citrome
core +1 more source
Clinical case of the use of cariprazine in treatment-resistant simple schizophrenia [PDF]
, 2022 A clinical case of the use of cariprazine in a patient with therapeutically resistant simple schizophrenia is considered. The debut and development of the disorder, pharmacological history are presented.
R. F. Nasyrova
core +2 more sources
European Psychiatry, 2022 Introduction Affective symptoms are a common feature of schizophrenia and define bipolar disorder. Alterations in dopamine neurotransmission and activity at D3-D2 receptors is associated with depressive symptoms providing the rationale for targeting D3 ...
R. Mcintyre +3 more
doaj +1 more source
Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine [PDF]
, 2019 OBJECTIVE: This study examined the chronic effects of aripiprazole and cariprazine on serotonin (5-HT1A and 5-HT2A) and glutamate (NMDA and AMPA) receptor subtypes.
Adham, N +4 more
core +1 more source
Mechanism of action of cariprazine [PDF]
CNS Spectrums, 2016 Cariprazine is a new therapeutic agent recently approved for the treatment of both schizophrenia and manic or mixed episodes associated with bipolar disorder, and is under investigation for the treatment of both bipolar depression and major depressive disorder.
openaire +2 more sources
Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
Frontiers in Psychiatry, 2022 Dopamine receptor partial agonists (DRPAs; aripiprazole, brexpiprazole, and cariprazine) constitute a novel class of antipsychotics. Although they share a similar mechanism of action, DRPAs differ in their pharmacodynamics, pharmacokinetics, drug ...
Pavel Mohr +4 more
doaj +1 more source